Switch to
More onapp

How to use scorecard? Learn more

Concord Biotech Ltd

CONCORDBIO
Health CarePharmaceuticals
SmallcapWith a market cap of ₹20,099 cr, stock is ranked 350
High RiskStock is 3.23x as volatile as Nifty
1,900.4563.50 (+3.46%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹20,099 cr, stock is ranked 350
High RiskStock is 3.23x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
64.18
PB RatioPB Ratio
13.17
Dividend YieldDiv. Yield
0.46%
Sector PESector PE
51.22
Sector PBSector PB
6.55
Sector Div YldSctr Div Yld
0.48%

Forecast & RatingsDetailed Forecast 

67%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Concord Biotech Limited, a biopharma company, engages in R&D, manufacturing, and marketing of pharmaceutical products in diverse therapeutic segments.

Financial TrendFinancial statements 

20212022202320240.630.740.891.050.240.170.240.31
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Trading Window-XBRL 
Announced OnSep 25, 2024

CONCORD BIOTECH LIMITED has informed the Exchange about Closure of Trading Window | Download

CONCORD BIOTECH LIMITED has informed the Exchange about Closure of Trading Window | Download

Trading Window 
Announced OnSep 25, 2024

Concord Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 | Download

Concord Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 | Download

Cash Dividend 
Ex. DateJun 21, 2024

Final • Div/Share: ₹ 8.75

See all events